Oral neratinib regulatory update

Puma said it will delay an NDA submission for oral neratinib to treat breast cancer to mid-2016 from 1Q16 to accommodate FDA’s request that it rewrite clinical sections of the application.

Read the full 315 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE